33224-99-6

Upstream product

• 64-67-5 diethyl sulfate 
• 611-71-2 MANDELIC ACID 
• 4870-65-9 2-bromophenylacetic acid 
• 75-03-6 ethyl iodide 
• 97415-09-3 (R)-benzyl 2-hydroxy-2-phenyl-acetate 
• 611-71-2 (R)-Mandelic Acid 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 59214-70-9 3-bromobenzofuran 
• 74-96-4 ethyl bromide 
• 774-40-3 hydroxy-phenyl-acetic acid ethyl ester 

Downstream Products

• 774-48-1 (diethoxymethyl)benzene 
• 100-52-7 benzaldehyde 
• 50916-32-0 Ethoxy-phenyl-acetyl chloride 
• 33224-69-0 2-ethoxy-2-phenylethanenitrile 
• 33224-98-5 ethoxy-phenyl-acetic acid amide 
• 1338793-95-5 2-ethoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 156753-81-0 1,3-Diethoxy-1-phenyl-propan-2-one 
• 132685-44-0 phenyl-pyruvaldehyde bis-(4-nitro-phenylhydrazone) 
• 65792-30-5 methyl α-ethoxy-α-phenylacetate 

Relevant academic research and scientific papers

SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.

BORONIC ACID DERIVATIVES

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder abnomality or hematological malignancies.

1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.

Carry over of impurities: A detailed exemplification for glycopyrrolate (NVA237)

The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.

Photolysis of Alkoxyacetic Acids in the presence of Mercury(II) Oxide and Iodine

Homolytic decarboxylation of a series of alkoxyacetic acids has furnished alkoxyalkyl alkoxyacetates when no substituents were present at the 2-position.Electron donating and withdrawing 2-substituents, with the exception of trichloromethyl, afforded products due to fragmentation of the alkoxyacetic acids.The reaction pathway is rationalised on the basis of the reactivity of the alkoxyalkyl iodide intermediates.